New Migraine Medication

被引：1

作者：

Aschenbrenner, Diane S. ^{[1
]}

机构：

[1] Notre Dame Maryland Univ, Baltimore, MD 21210 USA

来源：

AMERICAN JOURNAL OF NURSING | 2020年 / 120卷 / 02期

关键词：

D O I：

10.1097/01.NAJ.0000654292.06762.bd

中图分类号：

R47 [护理学];

学科分类号：

1011 ;

摘要：

The Food and Drug Administration has approved lasmiditan (Reyvow), a new treatment for acute migraine. Patients must avoid driving or other activities requiring full mental alertness, such as operating heavy machinery, for a minimum of eight hours after taking lasmiditan.

引用

页码：20 / 21

页数：2

共 50 条

[1] Rimegepant (Vydura®), a new migraine medication
Buxeraud, Jacques
Faure, Sebastien
ACTUALITES PHARMACEUTIQUES, 2024, 63 (635): : 10 - 12
[2] Using a model to evaluate the treatment benefits of a new migraine medication
Runken, M. C.
Smith, T. W.
HEADACHE, 2008, 48 : S23 - S23
[3] Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse
Licia Grazzi
Susanna Usai
Neurological Sciences, 2014, 35 : 37 - 39
[4] Botulinum toxin A: a new option for treatment of chronic migraine with medication overuse
Grazzi, Licia
Usai, Susanna
NEUROLOGICAL SCIENCES, 2014, 35 : S37 - S39
[5] Excessive acute migraine medication use and migraine progression
Bigal, Marcelo E.
Lipton, Richard B.
NEUROLOGY, 2008, 71 (22) : 1821 - 1828
[6] EXCESSIVE ACUTE MIGRAINE MEDICATION USE AND MIGRAINE PROGRESSION
Sethi, Nitin K.
NEUROLOGY, 2009, 73 (09) : 738 - 738
[7] Medication use in adolescents with migraine
Winner, P
Gladstein, J
Hershey, AD
NEUROLOGY, 2002, 58 (07) : A131 - A132
[8] Medication overuse and chronic migraine
Vincent T. Martin
Current Pain and Headache Reports, 2009, 13 : 337 - 339
[9] Medication overuse and chronic migraine
Martin, Vincent T.
CURRENT PAIN AND HEADACHE REPORTS, 2009, 13 (05) : 337 - 339
[10] New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication
Diener, Hans Christoph
May, Arne
CEPHALALGIA, 2024, 44 (03)

← 1 2 3 4 5 →